Paper41364346
Overview of ocular toxicities associated with breast cancer therapies.
Greenberg MR and 2 others. Breast Cancer Res Treat, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Overview of ocular toxicities associated with breast cancer therapies. Papers, record 41364346. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41364346
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Eye Diseases | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Female | |
| Molecular Targeted Therapy |
Source PubMed
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36084384 | Current and future burden of breast cancer: Global statistics for 2020 and 2040. | Breast | 2022 | https://conductscience.org/library/papers/36084384 | PubMed |
| 2 | 15850816 | Sex hormone receptors in the human eye. | Surv Ophthalmol | 2005 | https://conductscience.org/library/papers/15850816 | PubMed |
| 3 | 40377437 | Influence of tamoxifen on ocular morphology and function. | Oncologist | 2025 | https://conductscience.org/library/papers/40377437 | PubMed |
| 4 | 31479143 | Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. | JAMA | 2019 | https://conductscience.org/library/papers/31479143 | PubMed |
| 5 | 36495379 | Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea. | Breast Cancer Res Treat | 2023 | https://conductscience.org/library/papers/36495379 | PubMed |
| 6 | 7929848 | Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. | J Clin Invest | 1994 | https://conductscience.org/library/papers/7929848 | PubMed |
| 7 | 9747868 | Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. | J Natl Cancer Inst | 1998 | https://conductscience.org/library/papers/9747868 | PubMed |
| 8 | 31813590 | Prevalence and Risk Factors of Tamoxifen Retinopathy. | Ophthalmology | 2020 | https://conductscience.org/library/papers/31813590 | PubMed |
| 9 | 36781026 | Tamoxifen retinopathy. | Surv Ophthalmol | 2023 | https://conductscience.org/library/papers/36781026 | PubMed |
| 10 | 34956737 | Update on Retinal Drug Toxicities. | Curr Ophthalmol Rep | 2021 | https://conductscience.org/library/papers/34956737 | PubMed |
| 11 | 30973440 | TAMOXIFEN-INDUCED CHORIORETINAL CHANGES: An Optical Coherence Tomography and Optical Coherence Tomography Angiography Study. | Retina | 2020 | https://conductscience.org/library/papers/30973440 | PubMed |
| 12 | 35246390 | Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist. | Clin Breast Cancer | 2022 | https://conductscience.org/library/papers/35246390 | PubMed |
| 13 | 34972698 | Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review. | In Vivo | 2022 | https://conductscience.org/library/papers/34972698 | PubMed |
| 14 | 25597370 | Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors. | Cutan Ocul Toxicol | 2016 | https://conductscience.org/library/papers/25597370 | PubMed |
| 15 | 37931898 | Risk of ocular adverse events with aromatase inhibitors. | Can J Ophthalmol | 2024 | https://conductscience.org/library/papers/37931898 | PubMed |
| 16 | 21819259 | Breast cancer medications and vision: effects of treatments for early-stage disease. | Curr Eye Res | 2011 | https://conductscience.org/library/papers/21819259 | PubMed |
| 17 | 20470238 | Exemestane-induced corneal epithelial changes. | Cutan Ocul Toxicol | 2010 | https://conductscience.org/library/papers/20470238 | PubMed |
| 18 | 34646621 | Review of the Literature on Ocular Complications Associated With Aromatase Inhibitor Use. | Cureus | 2021 | https://conductscience.org/library/papers/34646621 | PubMed |
| 19 | 28680952 | A Review of Fulvestrant in Breast Cancer. | Oncol Ther | 2017 | https://conductscience.org/library/papers/28680952 | PubMed |
| 20 | 35584336 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35584336 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41898248 | Ocular Toxicities of Anticancer Therapies in the Era of Precision Oncology: A Practical, Clinically Oriented Narrative Review. | Biomedicines | 2026 | https://conductscience.org/library/papers/41898248 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41364346
GET https://conductscience.org/api/papers/v1/41364346/references?page=2